Table 2 CSF characteristics at the time of the CellSearch® technology analysis
Inclusion number, date of CSF sampling | Treatment received for LM at the time of CSF sampling for CVT | Biochemical CSF analysis | Cytomorphological CSF analysis | Enumeration of CSFTC with the CellSearch® Veridex technology |
|---|---|---|---|---|
03 - 01 | IV paclitaxel for 2 months then | Proteinorachia: 0.22 g/L | No malignant cell (10 mL) | 0 CSFTC per mL |
carboplatin | Glycorachia: 3.5 mmol/L | |||
No IT chemotherapy | Chlorurorachia: 121 mol/L | |||
05 - 01 | IV paclitaxel since LM diagnosis | Proteinorachia: 1.13 g/L | Presence of malignant cells (10 mL) | 626 CSFTC per mL |
No IT chemotherapy | Glycorachia: 2.4 mmol/L | |||
Chlorurorachia: 121 mol/L | ||||
05 - 02 | IV paclitaxel since LM diagnosis | Proteinorachia: 1.42 g/L | Presence of malignant cells (10 mL) | 1600 CSFTC per mL |
No IT chemotherapy | Glycorachia: 1.8 mmol/L | |||
Chlorurorachia: 117 mol/L | ||||
05 - 03 | IV paclitaxel since LM diagnosis | Proteinorachia: 2.90 g/L | No malignant cell (10 mL) | 2100 CSFTC per mL |
No IT chemotherapy | Glycorachia: 0.3 mmol/L | |||
Chlorurorachia: 118 mol/L | ||||
06 - 01 | None | Proteinorachia: 0.51 g/L | Presence of malignant cells (3 mL) | 7 CSFTC per mL |
Glycorachia: 3.7 mmol/L | ||||
Chlorurorachia: 126 mol/L | ||||
09 - 01 | None | Proteinorachia: 1.90 g/L | Presence of malignant cells (6 mL) | 208 CSFTC per mL |
Glycorachia: 3.3 mmol/L | ||||
Chlorurorachia: 110 mol/L | ||||
09 - 02 | Oral vinorelbine | Proteinorachia: 1.64 g/L | Not interpretable (10 mL) | 130 CSFTC per mL |
IT liposomal cytarabine (X1) | Glycorachia: 4.9 mmol/L | |||
Chlorurorachia: 108 mol/L | ||||
09 -03 | Oral navelbine | Proteinorachia: NA | Presence of malignant cells (10 mL) | 75 CSFTC per mL |
IT liposomal cytarabine (X2) | Glycorachia: NA | |||
Chlorurorachia: NA | ||||
09 -04 | Oral navelbine | Proteinorachia: 1.88 g/L | Presence of malignant cells (10 mL) | 82 CSFTC per mL |
IT liposomal cytarabine (X3) | Glycorachia: 4.5 mmol/L | |||
Chlorurorachia: 116 mol/L | ||||
10 - 01 | None | Proteinorachia: 0.80 g/L | Presence of malignant cells (5 mL) | 0.2 CTC per mL |
Glycorachia: 3.4 mmol/L | ||||
Chlorurorachia: 121 mol/L | ||||
10 - 02 | FEC 50 | Proteinorachia: 0.90 g/L | Presence of malignant cells (6 mL) | 0.4 CSFTC per mL |
IT liposomal cytarabine (X1) | Glycorachia: 3.2 mmol/L | |||
Chlorurorachia: 120 mol/L | ||||
11 - 01 | None | Proteinorachia: 7.08 g/L | Presence of malignant cells (6 mL) | 478 CSFTC per mL |
Glycorachia: 2 mmol/L | ||||
Chlorurorachia: 113 mol/L | ||||
11 - 02 | Capecitabine | Proteinorachia: 9.04 g/L | Presence of malignant cells (8 mL) | 940 CSFTC per mL |
No IT chemotherapy | Glycorachia: 3.2 mmol/L | |||
Chlorurorachia: 100 mol/L | ||||
12 - 01 | None | Proteinorachia: 0.39 g/L | Presence of malignant cells (10 mL) | 5 CSFTC per mL |
Glycorachia: 5.4 mmol/L | ||||
Chlorurorachia: 119 mol/L | ||||
12 - 02 | Oral capecitabine + lapatinib | Proteinorachia: 0.21 g/L | No malignant cells (8 mL) | 0 CSFTC per mL |
IT liposomal cytarabine (X1) | Glycorachia: 5.4 mmol/L | |||
Chlorurorachia: 119 mol/L | ||||
13 - 01 | None | Proteinorachia: 8.84 g/L | Presence of malignant cells (7 mL) | 1560 CSFTC per mL |
Glycorachia: 2.4 mmol/L | ||||
Chlorurorachia: 106 mol/L |